Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Treatment of genetic disease such as the bleeding disorder hemophilia B [deficiency in blood coagulation factor IX (F.IX)] by gene replacement therapy is hampered by the risk of immune responses to the therapeutic gene product and to the gene transfer vector. Immune competent mice of two different strains were tolerized to human F.IX by hepatic gene transfer mediated by adenoassociated viral vector. These animals were subsequently challenged by systemic administration of an E1/E3-deleted adenoviral vector, which is known to induce a cytotoxic T lymphocyte response to the transgene product. Immune tolerance prevented cytotoxic T lymphocyte activation to F.IX and CD8 + cellular infiltrates in the liver. Moreover, a sustained and substantial increase in hepatic F.IX expression from the adenoviral vector was achieved despite in vitro T cell responses to adenoviral antigens. Cytolytic responses to therapeutic and to viral vector-derived antigens had been prevented in vivo by activation of regulatory CD4 + T cells, which mediated suppression of inflammatory lymphocyte responses to the liver. This result suggests that augmentation of regulatory T cell activation should provide new means to avoid destructive immune responses in gene transfer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mouse studies have shown liver-directed AAV gene therapy results in tolerogenic responses by the induction of Tregs,52, 53, 54, 55, 56, 57, 58, 59”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [54]
Citations
Cites
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationHori, S., Nomura, T., & Sakaguchi, S. (2017) · The Journal of Immunology · doi:10.1093/jimmunol/198.3.981 · Cited by 1,066
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationYang, Y., Ertl, H. C. J., & Wilson, J. M. (1994) · Immunity · doi:10.1016/1074-7613(94)90074-4 · Cited by 611
Jooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470
Induction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466
Self-citationDifferential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394
Yang, Y., Jooss, K. U., Su, Q., Ertl, H. C. J., & Wilson, J. M. (1996) · PubMed · Cited by 375
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Self-citation
Research works printed but not linked: 2
- Y. Yang, K. U. Jooss, Q. Su, H. C. Ertl, J. M. Wilson Gene Ther 3, 137–144 (1996).
- C. S. Manno, G. F. Pierce, B. Glader, V. R. Arruda, M. V. Ragni, J. Rasko, M. Ozelo, K. Hoots, P. Blatt, B. Konkle, et al. Nat. Med, 2006).
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Self-citationNiemeyer, G. P., Herzog, R. W., Mount, J., Arruda, V. R., Tillson, D. M., Hathcock, J., van Ginkel, F. W., High, K. A., & Lothrop, C. D. (2009) · Blood · doi:10.1182/blood-2008-10-181479 · Cited by 276
Self-citationMingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254
Self-citationA microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Brown, B. D., Cantore, A., Annoni, A., Sergi, L. S., Lombardo, A., Della Valle, P., D'Angelo, A., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2007-03-078493 · Cited by 252
Breous, E., Somanathan, S., Vandenberghe, L. H., & Wilson, J. M. (2009) · Hepatology · doi:10.1002/hep.23043 · Cited by 237
Cao, O., Dobrzynski, E., Wang, L., Nayak, S., Mingle, B., Terhorst, C., & Herzog, R. W. (2007) · Blood · doi:10.1182/blood-2007-02-073304 · Cited by 220
Self-citationVandendriessche, T., Thorrez, L., Acosta‐Sanchez, A., Petrus, I., Wang, L., Ma, L., De Waele, L., Iwasaki, Y., Gillijns, V., Wilson, J. M., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02220.x · Cited by 209
Self-citationInnate Immune Responses to AAV Vectors
Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178
Self-citationUpdate on clinical gene therapy for hemophilia
Perrin, G. Q., Herzog, R. W., & Markusic, D. M. (2019) · Blood · doi:10.1182/blood-2018-07-820720 · Cited by 175
Self-citationMartino, A. T., Basner-Tschakarjan, E., Markusic, D. M., Finn, J. D., Hinderer, C., Zhou, S., Ostrov, D. A., Srivastava, A., Ertl, H. C. J., Terhorst, C., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460733 · Cited by 162
Self-citationTreatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“Activation of regulatory T cells also suppressed inflammatory cellular immune responses against hepatocytes transduced with F.IX expressing vectors (Dobrzynski et al. 2006).”
BackgroundSelf-citationThe Complex and Evolving Story of T cell Activation to AAV Vector-encoded Transgene Products
Mays, L. E., & Wilson, J. M. (2011) · Molecular Therapy · doi:10.1038/mt.2010.250 · Cited by 125
Capsid antibodies to different adeno-associated virus serotypes bind common regions
Gurda, B. L., DiMattia, M. A., Miller, E. B., Bennett, A., McKenna, R., Weichert, W. S., Nelson, C. D., Chen, W.-J., Muzyczka, N., Olson, N. H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00622-13 · Cited by 127
Hepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
LoDuca, P., Hoffman, B., & Herzog, R. (2009) · Current Gene Therapy · doi:10.2174/156652309787909490 · Cited by 114
Self-citationEffective gene therapy for haemophilic mice with pathogenic factor IX antibodies
Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., & Herzog, R. W. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302859 · Cited by 116
“…by use of capsid sequences engineered to reduce MHC I presentation (Markusic et al, 2010; Martino et al, 2013; Zhong et al, 2008). is a critical component of the mechanism of tolerance induction by hepatic AAV gene transfer (Hoffman et al, 2011; Cao et al, 2007; Dobrzynski et al, 2004, 2006).”
InfluentialSelf-citationPre-existing AAV Capsid-specific CD8+ T Cells are Unable to Eliminate AAV-transduced Hepatocytes
Li, H., Murphy, S. L., Giles-Davis, W., Edmonson, S., Xiang, Z., Li, Y., Lasaro, M. O., High, K. A., & Ertl, H. C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300090 · Cited by 108
Lin, S.-W., Hensley, S. E., Tatsis, N., Lasaro, M. O., & Ertl, H. C. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33138 · Cited by 88
“Previous gene therapy studies have shown that regulatory CD4+ T cells induce tolerance to the transgene product (29, 30).”
BackgroundImproved Induction of Immune Tolerance to Factor IX by Hepatic AAV-8 Gene Transfer
Cooper, M., Nayak, S., Hoffman, B. E., Terhorst, C., Cao, O., & Herzog, R. W. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.161 · Cited by 90
Self-citationLi, C., Hirsch, M., Asokan, A., Zeithaml, B., Ma, H., Kafri, T., & Samulski, R. J. (2007) · Journal of Virology · doi:10.1128/jvi.00529-07 · Cited by 87
Liver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
Quintavalle, G., Castaman, G., Baldacci, E., Ferretti, A., Riccardi, F., Tagliaferri, A., & Santoro, C. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1660817 · Cited by 83
Hoffman, B. E., Martino, A. T., Sack, B. K., Cao, O., Liao, G., Terhorst, C., & Herzog, R. W. (2011) · Molecular Therapy · doi:10.1038/mt.2011.33 · Cited by 72
Self-citationDevelopment of gene transfer for induction of antigen-specific tolerance
Sack, B. K., Herzog, R. W., Terhorst, C., & Markusic, D. M. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.13 · Cited by 70
Self-citationMcIntosh, J. H., Cochrane, M., Cobbold, S., Waldmann, H., Nathwani, S. A., Davidoff, A. M., & Nathwani, A. C. (2012) · Gene Therapy · doi:10.1038/gt.2011.64 · Cited by 70
Mays, L. E., Wang, L., Lin, J., Bell, P., Crawford, A., Wherry, E. J., & Wilson, J. M. (2014) · Molecular Therapy · doi:10.1038/mt.2013.134 · Cited by 62
Self-citationStrategies to Modulate Immune Responses: A New Frontier for Gene Therapy
Arruda, V. R., Favaro, P., & Finn, J. D. (2009) · Molecular Therapy · doi:10.1038/mt.2009.150 · Cited by 66
Boisgerault, F., Gross, D.-A., Ferrand, M., Poupiot, J., Darocha, S., Richard, I., & Galy, A. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.208 · Cited by 63
Immune tolerance in haemophilia: the long journey to the fork in the road
DiMichele, D. M. (2012) · British Journal of Haematology · doi:10.1111/bjh.12028 · Cited by 60
Complexity of immune responses to AAV transgene products – Example of factor IX
Herzog, R. W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.05.006 · Cited by 60
Self-citationImmune tolerance induction in haemophilia: evidence and the way forward
Michele, D. M. D. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04349.x · Cited by 59
Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment
Pierce, G. F., Lillicrap, D., Pipe, S. W., & VandenDriessche, T. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02410.x · Cited by 58
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
Self-citationGreig, J. A., Peng, H., Ohlstein, J., Medina-Jaszek, C. A., Ahonkhai, O., Mentzinger, A., Grant, R. L., Roy, S., Chen, S.-J., Bell, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112268 · Cited by 55
Martino, A. T., Nayak, S., Hoffman, B. E., Cooper, M., Liao, G., Markusic, D. M., Byrne, B. J., Terhorst, C., & Herzog, R. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006376 · Cited by 54
Self-citationSomanathan, S., Breous, E., Bell, P., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.40 · Cited by 54
Role of regulatory T cells in tolerance to coagulation factors
CAO, O., LODUCA, P. A., & HERZOG, R. W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03417.x · Cited by 54
Self-citationInnate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
“65 We now know that the liver is able to form analogous structures and acquire functions in T cell priming normally attributed to lymphoid organs.”
Self-citationChuah, M., Evens, H., & VandenDriessche, T. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12215 · Cited by 59
Gene therapy strategies for hemophilia: benefits versus risks
Petrus, I., Chuah, M., & VandenDriessche, T. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1500 · Cited by 51
Liver type I regulatory T cells suppress germinal center formation in HBV-tolerant mice
Xu, L., Yin, W., Sun, R., Wei, H., & Tian, Z. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306437110 · Cited by 45
DiMichele, D. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02474.x · Cited by 45
Muscle as a Target for Supplementary Factor IX Gene Transfer
Hoffman, B. E., Dobrzynski, E., Wang, L., Hirao, L., Mingozzi, F., Cao, O., & Herzog, R. W. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.042 · Cited by 44
Self-citationArjomandnejad, M., Sylvia, K., Blackwood, M., Nixon, T., Tang, Q., Muhuri, M., Gruntman, A. M., Gao, G., Flotte, T. R., & Keeler, A. M. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.010 · Cited by 44
Astermark, J., Lacroix‐Desmazes, S., & Reding, M. T. (2008) · Haemophilia · doi:10.1111/j.1365-2516.2008.01711.x · Cited by 51
Greig, J. A., Wang, Q., Reicherter, A. L., Chen, S.-J., Hanlon, A. L., Tipper, C. H., Clark, K. R., Wadsworth, S., Wang, L., & Wilson, J. M. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.128 · Cited by 40
Self-citationNakai, M., Komiya, K., Murata, M., Kimura, T., Kanaoka, M., Kanegae, Y., & Saito, I. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.085 · Cited by 43
Gene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
Self-citationPerrin, G. Q., Zolotukhin, I., Sherman, A., Biswas, M., de Jong, Y. P., Terhorst, C., Davidoff, A. M., & Herzog, R. W. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.83 · Cited by 40
Self-citationPre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
Basner-Tschakarjan, E., Bijjiga, E., & Martino, A. T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00028 · Cited by 39
AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
Palaschak, B., Herzog, R. W., & Markusic, D. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_20 · Cited by 40
Self-citationPendaries, V., Gasc, G., Titeux, M., Leroux, C., Vitezica, Z. G., Mejía, J. E., Décha, A., Loiseau, P., Bodemer, C., Prost‐Squarcioni, C., et al. (2010) · Gene Therapy · doi:10.1038/gt.2010.36 · Cited by 40
Sawamoto, K., Karumuthil‐Melethil, S., Khan, S. A., Stapleton, M., Bruder, J. T., Danos, O., & Tomatsu, S. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.015 · Cited by 39
Antigen‐specific Treg impair CD8+ T‐cell priming by blocking early T‐cell expansion
Chappert, P., Leboeuf, M., Rameau, P., Lalfer, M., Desbois, S., Liblau, R., Danos, O., Davoust, J. M., & Gross, D. (2010) · European Journal of Immunology · doi:10.1002/eji.200839107 · Cited by 41
Measuring Immune Responses to Recombinant AAV Gene Transfer
Martino, A. T., Herzog, R. W., Anegon, I., & Adjali, O. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_11 · Cited by 36
Self-citationXu, L., Mei, M., Haskins, M. E., Nichols, T. C., O’Donnell, P., Cullen, K., Dillow, A. M., Bellinger, D. A., & Ponder, K. P. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2006.09.010 · Cited by 37
Anguela, X. M., Tafuro, S., Roca, C., Callejas, D., Agudo, J., Obach, M., Ribera, A., Ruzo, A., Mann, C. J., Casellas, A., et al. (2013) · Diabetes · doi:10.2337/db11-1776 · Cited by 35
Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
Sherman, A., Biswas, M., & Herzog, R. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01604 · Cited by 33
Self-citationLiver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia
Markusic, D. M., & Herzog, R. W. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-009 · Cited by 36
Self-citationHow not to be seen: immune-evasion strategies in gene therapy
Zaldumbide, A., & Hoeben, R. C. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303082 · Cited by 39
BALB/c Mice Show Impaired Hepatic Tolerogenic Response Following AAV Gene Transfer to the Liver
Breous, E., Somanathan, S., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.301 · Cited by 33
Selot, R., Hareendran, S., & Jayandharan, G. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140327141710 · Cited by 31
Liao, G., O’Keeffe, M. S., Wang, G., van Driel, B., Malefyt, R. D. W., Reinecker, H., Herzog, R. W., & Terhorst, C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00035 · Cited by 32
Self-citationHemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
Gene Therapy for Pompe Disease: The Time is now
Colella, P., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.109 · Cited by 37
Self-citationRecent Progress in Gene Therapy for Hemophilia
Chuah, M., Nair, N., & VandenDriessche, T. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.088 · Cited by 34
The immune response to the fVIII gene therapy in preclinical models
Patel, S. R., Lundgren, T. S., Spencer, H. T., & Doering, C. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00494 · Cited by 29
“Similarly, several studies demonstrate that gene transfer of human fIX using liver-tropic AAV promotes generation of Tregs that have the capacity to suppress antibody formation to human fIX following transfer into naïve hemophilia B mice (71, 79, 80).”
BackgroundAAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?
van der Laan, L. J. W., Wang, Y., Tilanus, H. W., Janssen, H. L. A., & Pan, Q. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.548799 · Cited by 33
Poupiot, J., Costa Verdera, H., Hardet, R., Colella, P., Collaud, F., Bartolo, L., Davoust, J., Sanatine, P., Mingozzi, F., Richard, I., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.012 · Cited by 24
Self-citationHaemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 28
Borkham‐Kamphorst, E., Huss, S., de Leur, E. V., Haas, U., & Weiskirchen, R. (2012) · Liver International · doi:10.1111/j.1478-3231.2012.02837.x · Cited by 24
Liu, L., Liu, H., Mah, C. S., & Fletcher, B. S. (2009) · Gene Therapy · doi:10.1038/gt.2009.13 · Cited by 23
Gernoux, G., Guilbaud, M., Dubreil, L., Larcher, T., Babarit, C., Ledevin, M., Jaulin, N., Planel, P., Moullier, P., & Adjali, O. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.070 · Cited by 23
Valentino, L. A., Ozelo, M. C., Herzog, R. W., Key, N. S., Pishko, A. M., Ragni, M. V., Samelson‐Jones, B. J., & Lillicrap, D. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.05.011 · Cited by 21
Self-citationOptimized Adeno-Associated Viral-Mediated Human Factor VIII Gene Therapy in Cynomolgus Macaques
Greig, J. A., Nordin, J. M. L., White, J. W., Wang, Q., Bote, E., Goode, T. L., Calcedo, R., Wadsworth, S. C., Wang, L., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.080 · Cited by 17
Self-citationTolerance induction in hemophilia: innovation and accomplishments
Sherman, A., Biswas, M., & Herzog, R. W. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000446 · Cited by 18
Self-citationSuppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice
Lim, J., Kishnani, P. S., & Sun, B. (2022) · JCI Insight · doi:10.1172/jci.insight.152970 · Cited by 16
Kamala, O., Malik, T. H., Hallam, T. M., Cox, T. E., Yang, Y., Vyas, F., Luli, S., Connelly, C., Gibson, B. G., Smith‐Jackson, K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752916 · Cited by 17
Gene therapy – are we ready now?
Kaczmarek, R. (2022) · Haemophilia · doi:10.1111/hae.14530 · Cited by 15
Choi, S. J., Yi, J. S., Lim, J., Tedder, T. F., Koeberl, D. D., Jeck, W. R., Desai, A. K., Rosenberg, A. S., Sun, B., & Kishnani, P. S. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3509 · Cited by 14
Structure of the AAVhu.37 capsid by cryoelectron microscopy
Kaelber, J. T., Yost, S. A., Webber, K., Firlar, E., Liu, Y., Danos, O., & Mercer, A. C. (2020) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x20000308 · Cited by 15
Lu, Z., & Ghazizadeh, S. (2007) · Molecular Therapy · doi:10.1038/mt.sj.6300086 · Cited by 14
Gene therapy for treatment of inherited haematological disorders
Herzog, R. W., Cao, O., Hagstrom, J. N., & Wang, L. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.5.509 · Cited by 15
Self-citationSack, B. K., Wang, X., Sherman, A., Rogers, G. L., & Markusic, D. M. (2014) · Haemophilia · doi:10.1111/hae.12522 · Cited by 10
Coaxing the liver into preventing autoimmune disease in the brain
Hoffman, B. E., & Herzog, R. W. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37079 · Cited by 12
Self-citationChan, C.-C., Lai, C., Wu, C.-J., Chen, L., Tao, M., & Kuo, M. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.161 · Cited by 9
(2007) · Wiley eBooks · doi:10.1002/9780470184585 · Cited by 8
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients.
Khalilian, S., Motovali-Bashi, M., & Rezaie, H. (2020) · PubMed Central · doi:10.22088/ijmcm.bums.9.1.33 · Cited by 8
Trevisan, B., Rodriguez, M., Medder, H., Lankford, S. S., Combs, R., Owen, J., Atala, A., Porada, C. D., & Almeida-Porada, G. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070476 · Cited by 5
Single-dose AAV vector gene immunotherapy to treat food allergy
Gonzalez-Visiedo, M., Li, X., Muñoz-Melero, M., Kulis, M. D., Daniell, H., & Markusic, D. M. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.008 · Cited by 5
Matsushima, S. K., Shimada, Y., Kinoshita, M., Nagashima, T., Okamoto, S., Iizuka, S., Takagi, H., Iizuka, S., Higuchi, T., Hioki, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci180724 · Cited by 3
Sharma, D.-C., Al-khalidi, R. A. A., Edgar, S., An, Q., Wang, Y., Young, C., Nowis, D., & Górecki, D. C. (2016) · Gene Therapy · doi:10.1038/gt.2016.82 · Cited by 3
Thomson, C. W., Mossoba, M. E., Siatskas, C., Chen, W., Sung, A., Medin, J. A., & Zhang, L. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300082 · Cited by 3
Upregulation of CD8+ regulatory T cells following liver-directed AAV gene therapy
Gaddie, C. D., Senior, K. G., Chan, C. T., Hoffman, B. E., & Keeler, G. D. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104806 · Cited by 2
Inhibitors to Factor VIII/IX: Immune Tolerance
DiMichele, D. (2010) · Wiley eBooks · doi:10.1002/9781444318555.ch10 · Cited by 3
Inhibitors to Factor VIII/IX: Immune Tolerance
DiMichele, D. (2014) · Wiley eBooks · doi:10.1002/9781118398258.ch9 · Cited by 2
Increased gene therapy efficacy through the use of extended half-life clotting factors
Wolf, D. D., Nguyen, P. A., Nair, N., Gao, F., Bheemsetty, V. A., Samara-Kuko, E., Chuah, M., & VandenDriessche, T. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018891 · Cited by 1
Ashley, S. N., Somanathan, S., Hinderer, C. J., Arias, M., McMenamin, D., Draper, C., & Wilson, J. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601131 · Cited by 1
Bello, A. J. A. (2014) · Mspace (University of Manitoba) · Cited by 1
Induction of Immunological Tolerance to Transgene Products
Sack, B. K., Markusic, D. M., & Herzog, R. W. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5480-9_15
Self-citationTreating Hemophilia by Gene Therapy
Porada, C. D., Ignacio, G., Atala, A., & Almeida-Porada, G. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800548-4.00012-7
Metadata
- Authors
- Dobrzynski, E., Fitzgerald, J. C., Cao, O., Mingozzi, F., Wang, L., & Herzog, R. W.
- Affiliations
- Children's Hospital of Philadelphia (US)
- University of Florida (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2006-03-10
- Volume
- 103
- Issue
- 12
- Pages
- 4592-4597
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1993774764
- Cited by
- 105
- References
- 31
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 4 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 3 · 2015: 2 · 2014: 10 · 2013: 8 · 2012: 5
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL078810)
- National Institute of Allergy and Infectious Diseases (R01 AI/HL 51390-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- hemophilia B, factor IX, gene replacement therapy, immune tolerance, regulatory T cells, cytotoxic T lymphocytes, adeno-associated virus vectors, adenoviral vector, CD4+ T cells, CD8+ T cell infiltration
- MeSH terms
- Adenoviridae, Animals, Cytotoxicity, Immunologic, Factor IX, Genetic Vectors, Immune Tolerance, Immunosuppression Therapy, Male, Mice, Inbred Strains, T-Lymphocytes, Cytotoxic, Genetic Therapy, Gene Transfer Techniques, Adoptive Transfer, Hepatocytes, T-Lymphocytes, Regulatory, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.